IDEXX Laboratories, Inc. (IDXX)

NASDAQ · Health Care · market cap 44.45B

Share price

$506.48

At the last nightly close

Intrinsic value

$379.46

Range $231.38 – $267.86 before any credit for growth. The figure above credits what the franchise record earns, which is why it sits outside that range.

Margin of safety

-25.1%

($379.46 − $506.48) ÷ $506.48

EV / EBIT

85.1

On the median operating profit of 15 fiscal years through 2025.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.

Key metrics

Price / earnings35.6
Price / book24.8
EV / EBITDA25.5
FCF / EV+0.7%
Return on equity+74.2%
Return on assets+27.1%
Debt / equity0.68
Gross margin+62.4%

Market position

52-week high$766.68
52-week low$504.70
From 52-week high-33.9%
RSI (14)34.6
200-day moving average$584.48

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY4.30B1.36B1.06B13.171.04B
2024-FY3.90B1.13B887.9M10.77798.1M
2023-FY3.66B1.10B845.0M10.17772.9M
2022-FY3.37B898.8M679.1M8.12384.1M
2021-FY3.22B932.0M744.8M8.60636.0M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedNovember 2, 2026
Consensus EPS estimate3.71

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on IDXX.

Run the board on IDXX

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.